During the corresponding time, Trinity Biotech Plc saw a revenue deteriorated by -28.87 % year on year, While revenue at the Trinity Biotech Plc's corporate clients
Trinity Biotech Plc's Comment on Sales, Marketing and Customers
The company operates in approximately 100 countries worldwide through its own sales force and a network of international distributors and strategic partners. It sells products directly in the United States, Brazil, the United Kingdom, France, and Germany, and through distributors and non-governmental organizations globally. Its principal markets include point-of-care and clinical laboratory diagnostics, with applications in infectious diseases, hemoglobin, autoimmune disorders, clinical chemistry, and blood bank screening. Key products include Uni-Gold™ HIV, a confirmatory HIV test widely used in sub-Saharan Africa for early detection and treatment intervention, and TrinScreen, an HIV screening test approved by the World Health Organization in February 2022 and commercially available since 2023. The company is also developing a continuous glucose monitoring device and related technologies to provide health and wellness insights.
Trinity Biotech plc, a biotechnology company based in Dublin, Ireland, has received timely approval from the World Health Organization (WHO) to initiate offshore manufacturing for its TrinScreen HIV and Uni-Gold HIV diagnostic tests. This development aligns with the company’s Comprehensive Transformation Plan and marks a significant step in enhancing the production capabilities of vital HIV diagnostic tools. Overview of Trinity Biotech’s Initiative As part of its ongoing efforts to optimize operational efficiency, Trinity Biotech has decided to transfer the manufacturing of its TrinScreen HIV and Uni-Gold HIV products to a lower-cost offshore manufacturing partner. This strategic move aims not only to re...
Trinity Biotech Announces Significant Q2 2024 Revenue Growth, UK Distribution Deal, and Plans for Expansion in Asia Dublin, Ireland, January 31, 2024 Trinity Biotech plc (Nasdaq: TRIB) is marking a period of significant milestones, showcasing robust financial growth and strategic partnerships that are setting the stage for an expansion in key international markets. Key Financial Performance in Q2 2024 Trinity Biotech announced that its preliminary revenues for the second quarter of 2024 are projected to fall between $15.5 million to $16.0 million. This anticipated revenue range represents a double-digit percentage increase year-over-year, underscoring the company’s upward trajectory and the efficacy ...
Trinity Biotech Plc Finalizes ADS Ratio Change, Offering Greater Value to InvestorsDublin, Ireland, Feb. 15, 2024 - Trinity Biotech Plc. (NASDAQ: TRIB), a leading biotechnology company, has announced the finalization of the effective date for its ratio change of its American depositary shares (ADSs). The change will now see one (1) ADS representing twenty (20) Class A ordinary shares, offering investors enhanced value and potential benefits. The ratio change is set to take place on February 23, 2024, on the Nasdaq Global Market, creating an exciting opportunity for both current and potential investors.This strategic move by Trinity Biotech Plc. aims to optimize the trading price of the ADSs and increase the ...
Trinity Biotech Announces Partnership with Bayer for Launch of CGM Biosensor Device in China and IndiaDublin, Ireland - January 31, 2024 - Trinity Biotech plc (Nasdaq: TRIB) has made an exciting revelation today as the company enters into a non-binding Letter of Intent with Bayer. This strategic partnership aims to launch a Continuous Glucose Monitoring (CGM) biosensor device in two of the largest and fastest-growing markets in the world - China and India. The collaboration comes on the heels of Trinity Biotech s recent acquisition of the CGM assets of Waveform Technologies, Inc., further solidifying the company s commitment to providing innovative solutions for diabetes management.Continuous Glucose Monitor...
Dublin-based medical diagnostics enterprise, Trinity Biotech, announced this week that they have commenced the shipping of their groundbreaking HIV screening test, TrinScreen HIV, to Kenya. This news comes as a significant development in the arena of disease diagnostics and marks a remarkable feat in the global fight against HIV/Aids.Trinity Biotech plc, a leading name in the development and manufacturing of diagnostic products for point-of-care and clinical laboratory markets, is known for its innovation in the medical field. The test, aptly named TrinScreen HIV, is the latest addition to its illustrious portfolio. This rapid HIV screening test is a testimony to the Company s pioneering technology and pursu...
Trinity Biotech Plc’s Comment on Sales, Marketing and Customers
The company operates in approximately 100 countries worldwide through its own sales force and a network of international distributors and strategic partners. It sells products directly in the United States, Brazil, the United Kingdom, France, and Germany, and through distributors and non-governmental organizations globally. Its principal markets include point-of-care and clinical laboratory diagnostics, with applications in infectious diseases, hemoglobin, autoimmune disorders, clinical chemistry, and blood bank screening. Key products include Uni-Gold™ HIV, a confirmatory HIV test widely used in sub-Saharan Africa for early detection and treatment intervention, and TrinScreen, an HIV screening test approved by the World Health Organization in February 2022 and commercially available since 2023. The company is also developing a continuous glucose monitoring device and related technologies to provide health and wellness insights.
Sources:
Trinity Biotech Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Trinity Biotech Plc’s corporate clients.
For your research, we’ve provided 9 tables on Trinity Biotech Plc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
56.24 %